PSA Velocity: What It Is and Why We Watch It

Most men who walk into my office for testosterone therapy ask about energy, libido, body fat, and mood. Almost nobody asks about the one number I probably watch more closely than any other on their labs. That number is PSA, and more specifically, how fast it's moving. We call that PSA velocity, and if you're a man over 40 thinking about TRT, it's worth understanding why I care about the slope of that line as much as the value itself.

I'm Dr. Farhan Abdullah. I'm an internal medicine physician, and I run Magnolia Functional Wellness here in Southlake. A big chunk of my practice is testosterone optimization for men, and one of the things I tell every new patient is that good TRT isn't just about the dose we start. It's about the monitoring we never stop. PSA velocity sits right at the center of that monitoring conversation, and it tends to get either ignored or badly misunderstood.

So let's clear it up. What is PSA velocity, why does a single PSA value rarely tell the whole story, and how do I actually use this in the clinic to keep men safe while they get the benefits of treatment?

What PSA Velocity Actually Measures

PSA stands for prostate-specific antigen, a protein made by the prostate gland that shows up in your bloodstream. A standard PSA test gives you a snapshot: a single number, usually reported in nanograms per milliliter. For decades, doctors leaned hard on cutoffs. Under 4.0 was "normal," over 4.0 meant "let's talk." Clean and simple, except the human body rarely cooperates with clean and simple.

Here's the problem with the snapshot approach. A man with a naturally large prostate might sit at a PSA of 3.8 his whole life and never have anything wrong. Another man might have a PSA of 1.2 that quietly climbs to 2.6 over eighteen months, still technically "normal," but that movement is a red flag worth investigating. The absolute number missed it. The trend caught it.

That's what PSA velocity is. It's the rate of change of your PSA over time, usually expressed in nanograms per milliliter per year. Instead of asking "is your PSA high," velocity asks "how quickly is your PSA rising." It treats your prostate as a story unfolding across multiple data points rather than a verdict delivered in one blood draw.

Why does the slope matter so much? Because benign processes and concerning ones tend to behave differently over time. An enlarging prostate from ordinary aging, what we call benign prostatic hyperplasia, usually nudges PSA up slowly and steadily. A more aggressive process can push that number up faster. Velocity gives us a way, imperfect but useful, to tell a gentle drift apart from a worrying sprint. Researchers like Dr. H. Ballentine Carter at Johns Hopkins spent years showing that men whose PSA rose more rapidly in the years before diagnosis tended to have more serious disease. The speed carried information the single value couldn't.

Why TRT Makes This Number Worth Watching

Now, why am I, a testosterone doctor, so fixated on this? Because testosterone and the prostate have a relationship, and ignoring it would be malpractice.

The prostate is an androgen-responsive organ. When you raise a hypogonadal man's testosterone from the basement back up to a healthy range, his prostate often responds by producing a bit more PSA. This is expected. It's not a sign that something has gone wrong. In most men, PSA rises modestly in the first three to six months of therapy and then settles into a new, stable baseline.

We have good data on this. A 2013 study published in BJU International by Raynaud and colleagues followed hypogonadal men through six years of transdermal testosterone treatment and found that PSA concentrations stayed remarkably stable over the long haul, with no runaway climbing once men were established on therapy. That kind of multi-year data is reassuring, and it's exactly why I don't panic over a small early bump.

The older fear here, the one a lot of men have absorbed from somewhere, is that testosterone "feeds" prostate cancer. The reality is more nuanced. The saturation model, supported by a lot of clinical work over the past two decades, suggests that prostate tissue gets saturated with androgen at relatively low testosterone levels. Push above that point and you're not pouring more fuel on a fire. Even men treated for prostate cancer have been studied on testosterone. A 2013 paper in the Journal of Urology by Pastuszak and colleagues looked at testosterone replacement in men after radical prostatectomy and found that while PSA did rise, cancer recurrence rates did not climb, even in higher-risk men. The authors were clear that this requires careful surveillance, and that's the whole point. Surveillance is what makes it safe.

So testosterone can raise PSA. That's a fact. The question is never simply "did your PSA go up." It's "did it go up the way we'd expect, or did it go up in a way that demands a closer look." Velocity is how I answer that question.

The Thresholds I Use in Practice

Let me get specific, because this is where the rubber meets the road. Before I ever write a testosterone prescription for a man, I want a baseline PSA. Not one number on the day we start. Ideally I want a sense of where he's been, and I want a confirmed starting point.

Once a man begins therapy, I recheck PSA at roughly three months, then at six months, and then on a regular cadence after that. Here's what I'm watching for. The Endocrine Society's clinical guidance flags a rise of more than 1.4 ng/mL within any twelve-month period as worth investigating. After the first six months, when the early bump should have settled, a sustained PSA velocity above about 0.4 ng/mL per year gets my attention. In the general screening world, older work used a threshold around 0.75 ng/mL per year for men with higher baseline values. These aren't magic numbers that automatically mean cancer. They're tripwires that tell me to slow down, repeat the test, and think.

And that's a crucial part of how velocity should be used. PSA is a noisy test. It bounces. A vigorous bike ride, recent ejaculation, a low-grade prostate infection, even a long Saturday in the saddle before a lab draw can nudge it up temporarily. One elevated reading is a reason to repeat, not a reason to spiral. Real velocity is calculated across multiple measurements over a meaningful stretch of time, not from two random data points a month apart.

I'll also point out that velocity is one tool among several. It works best alongside other context, things like your prostate size on exam, your family history, your free-PSA percentage, and how you feel. A rising velocity in a 52-year-old with a father and brother who both had prostate cancer carries more weight than the same slope in a man with no family history and a small prostate. Numbers don't get interpreted in a vacuum. They get interpreted against the whole man sitting in front of me, which is the part a lab printout can never do on its own.

What Happens When the Number Climbs Too Fast

If a man's PSA velocity crosses one of these thresholds and stays there on repeat testing, I don't reflexively stop his testosterone and send him on his way. I investigate. That might mean a digital rectal exam, a repeat confirmed PSA, sometimes a free-versus-total PSA ratio, and a conversation with a urologist I trust. The goal is to figure out what's driving the rise. Sometimes it's an enlarging prostate. Sometimes it's prostatitis. Occasionally it's something that genuinely needs a biopsy. The velocity didn't diagnose anything. It just told us where to point the flashlight.

What This Means If You're Considering TRT

Here's the takeaway I want you to walk away with. Testosterone therapy is not dangerous to your prostate when it's done by someone who's actually paying attention. The danger lives in unmonitored treatment, the kind you get from a slick clinic that hands you a vial, takes your money, and never looks back at your labs. I've inherited patients from exactly those setups, men who'd been on testosterone for two or three years and had never had a single follow-up PSA. That's the scenario that keeps me up at night, not the therapy itself.

Even the earliest studies understood this. Back in 1997, Svetec and colleagues published work in the Journal of Urology on parenteral testosterone replacement and PSA in hypogonadal men and found the changes were modest and manageable with monitoring. We've known how to do this responsibly for a long time. The science hasn't really changed. What's changed is how many places offer testosterone without the wraparound care that should come with it.

When you work with a physician who tracks your PSA velocity, you get the best of both worlds. You get the energy, the strength, the sharper focus, and the improved mood that properly dosed testosterone can deliver. And you get a safety net that catches problems early, often earlier than they'd be caught in a man not on therapy at all, simply because we're checking your labs on a schedule. Some of my patients, frankly, end up better screened for prostate issues after starting TRT than they ever were before, because nobody was watching that closely until they walked through our door.

At Magnolia Functional Wellness in Southlake, monitoring isn't an afterthought we tack onto your treatment. It's built into how we practice. If you're curious about whether testosterone therapy makes sense for you, and you want a clinic that treats your prostate health as seriously as your symptoms, that's exactly the kind of care we're here to provide. You can learn more about our approach to testosterone replacement therapy, and if you're a man over 30 weighing your options, our TRT guide for men in DFW covers what to expect before you ever start.

Your PSA is a story, not a snapshot. Velocity is how we read it. And reading it well is one of the quiet, unglamorous reasons that supervised testosterone therapy is both effective and safe.

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX